ArticleInfection and immunity2001
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA.Infection and immunity · 2025Article
- Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Applied microbiology and biotechnology · 2024Review
- OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans.NPJ vaccines · 2023Article
- A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis.Scientific reports · 2019Article
- Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.Infection and immunity · 2016Article
- Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.Infection and immunity · 2015Article
- Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.Infection and immunity · 2014Article
- Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.Vaccine · 2013Article
- Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.Infection and immunity · 2012Article
- Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice.Clinical and vaccine immunology : CVI · 2011Article
- Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group B.Vaccine · 2010Article
- De-N-acetylated sialic acid is immunogenic and elicits antibodies that are protective against Neisseria meningitidis.VacciMonitor · 2009Article
- Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.Infection and immunity · 2008Article
- Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.Clinical and vaccine immunology : CVI · 2008Article
- Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.The Journal of infectious diseases · 2005Article
- Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody.Infection and immunity · 2005Article
- Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.Infection and immunity · 2004Article
- GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence.Infection and immunity · 2004Article
- Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neisserial surface protein A (NspA) is currently being investigated with humans as a candidate vaccine for the prevention of meningococcal disease. Although NspA is highly conserved, the ability of anti-NspA antibodies to bind to or elicit complement-mediated bactericidal activity against diverse Neisseria meningitidis serogroup B strains is controversial. To evaluate strain differences in NspA surface accessibility and susceptibility to bactericidal activity, we prepared murine immunoglobulin G2a anti-NspA monoclonal antibodies (MAbs) and evaluated their functional activity against 10 genetically diverse N. meningitidis serogroup B strains. By colony Western blot, all 10 strains expressed NspA as detected by one or more MAbs. By flow cytometry, two MAbs were found to bind to the bacterial surface of 6 of the 10 strains. In addition, two strains showed variable NspA surface accessibility for the MAbs despite being uniformly positive for NspA expression by colony Western blotting. Only 4 of the 10 strains were susceptible to anti-NspA complement-mediated bacteriolysis. Passively administered MAb protected infant rats from developing bacteremia after challenge with N. meningitidis serogroup B strain 8047 (surface binding positive, susceptible to anti-NspA bacteriolysis), was poorly protective against strain BZ232 (surface binding variable, resistant to bacteriolysis), and did not protect against strain M986 (surface binding negative, resistant to bacteriolysis). Finally, NspA does not appear to be critical for causing bacteremia, as an NspA knockout from strain 8047 was highly virulent in infant rats. Taken together, these findings suggest that an NspA-based vaccine will need to incorporate additional antigens to elicit broad protection against N. meningitidis serogroup B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.